Purpose Anaplastic lymphoma kinase (ALK) rearrangement confers sensitivity to ALK inhibitors (ALKis) in non-small-cell lung cancer (NSCLC). Although several drugs provided an impressive outcome benefit, the most effective sequential strategy is still unknown. We describe outcomes of real-life patients according to the treatment strategy received. Patients We retrospectively collected 290 ALK rearranged advanced NSCLC diagnosed between 2011 and 2017 in 23 Italian institutions. Results After a median follow-up of 26 months, PFS for crizotinib and a new generation ALKis were 9.4 [CI 95% 7.9-11.2] and 11.1 months [CI 95% 9.2-13.8], respectively, while TTF were 10.2 [CI 95% 8.5-12.6] and 11.9 months [CI 95% 9.7-17.4], respectively, being consistent across the different settings. The composed outcomes (the sum of PFS or TTF) in patients treated with crizotinib followed by a new generation ALKis were 27.8 months [CI 95% 24.3-33.7] in PFS and 30.4 months [CI 95% 24.7-34.9] in TTF. The median OS from the diagnosis of advanced disease was 39 months [CI 95% 31.8-54.5]. Patients receiving crizotinib followed by a new generation ALKis showed a higher median OS [57 months (CI 95% 42.0-73.8)] compared to those that did not receive crizotinib [38 months (CI 95% 18.6-NR)] and those who performed only crizotinib as target agent [15 months (CI 95% 11.3-34.0)] (P < 0.0001). Conclusion The sequential administration of crizotinib and a new generation ALKis provided a remarkable clinical benefit in this real-life population, being an interesting option to consider in selected patients.
Introduction
Anaplastic lymphoma kinase (ALK) rearranged patients represent only 5% of non-small-cell lung cancers (NSCLCs) [1, 2] but, in the last 10 years, there has been an impressive revolution in their treatment strategy thanks to the approval of several ALK inhibitors (ALKis). Crizotinib was the first ALKi approved by the European Medicines Agency (EMA) as upfront treatment in 2012. More recently, 2 s generation ALKis, ceritinib and alectinib, were also registered in the same setting, as well as in crizotinib-resistant patients. Finally, later in 2018, the second generation ALKi brigatinib obtained the approval in crizotinib-progressing patients. No head-to-head comparison between ceritinib and crizotinib in first-line setting have been performed yet, but upfront alectinib and brigatinib were clearly shown to confer a better overall response rate (ORR), progression free survival (PFS) and central nervous system disease control compared to crizotinib [3] [4] [5] [6] . Unfortunately, no survival data are available at the present time. Moreover, other second (ensartinib) [7] or third (lorlatinib) [8] generation ALKis are currently coming on the stage, as well as several neurotropic tropomyosin receptor kinase (NTRK)/ALK/ROS proto-oncogene 1 (ROS1) pan-inhibitors such as entrectinib (NCT02097810) [9] or TPX-0005 (NCT03093116) [10] that already showed interesting results in patients progressing after one or more ALKis. Consequently, the therapeutic algorithm for ALK rearranged advanced NSCLC patients is becoming more and more intricate and, considering the lack of survival data from large phase III trials, the correct sequential strategy have yet to be defined. In particular, the role of crizotinib in the new treatment algorithm is not clear being, new generation ALKi, capable to overcome crizotinib acquired resistance mechanisms and to be efficacious either in crizotinib-naïve and resistant patients [11] [12] [13] with particular activity on brain localization. Keeping or not crizotinib in the modern therapeutic strategy for ALK rearranged advanced NSCLC patients is debated.
This analysis aims to retrospectively describe outcomes of real-life ALK rearranged advanced NSCLC patients according to the treatment strategy received.
Methods

Patients and data collection
We retrospectively collected 290 ALK rearranged advanced NSCLCs diagnosed between January, 1st 2011 and December, 31st 2017 in 23 Italian institutions. Patients had a cytological or histological diagnosis of advanced NSCLC, staged according to the 7th edition TNM of the American Joint Committee on Cancer [14] . Patients underwent to diagnostic procedures, molecular evaluations and treatments choices according to the local practice and national guidelines. Certified immunohistochemistry and/or break-apart fluorescence in situ hybridization were used to assess the presence of ALK rearrangements (Table S1 ). This study was approved by the ethical committee of each oncologic center involved. Patients gave written informed consent before inclusion in the study. Each investigator sent the anonymized data to the San Luigi Hospital that had full access to the dataset as coordinator center. The following data were collected: age at time of diagnosis, gender, TNM stage according to the 7th edition of the American Joint Committee on Cancer, metastatic sites at diagnosis, pathological diagnosis according to the 2011 International Association for the Study of Lung Cancer/European Respiratory Society classification, date of advanced or recurrent NSCLC diagnosis and molecular assessment during the history disease focusing mostly on ALK rearrangements. Information about anticancer treatment were also collected including anticancer systemic treatments, date of disease progression and treatment discontinuation, date of death or last follow-up evaluation.
Radiological assessments were evaluated by each investigator locally, without a central review.
Italian therapeutic scenario
In Italy, crizotinib got the reimbursement as second-line for ALK rearranged patients since 2015, while it became available as upfront treatment only during the last part of the study along with the new generation ALKis ceritinib and alectinib. Other more recently developed ALKis (brigatinib, lorlatinib, ensartinib, entrectinib) were only available within clinical trials or off-label programs.
Objectives and statistical analysis
The primary objective was to describe the overall survival (OS) of ALK rearranged patients according to their therapeutic strategy. Likewise, secondary objectives were to describe PFS and the time to treatment failure (TTF) of ALKis in according to the line of treatment along with the composed PFS and TTF of crizotinib followed by a new generation (second or third generations) ALKis.
Descriptive analysis, including median and range for continuous variables or frequencies and percentage for categorical variables, were used. PFS was defined as the time from the ALKis starting to the date of progression, death, or last follow-up. TTF represented the time from the ALKis beginning to the treatment withdrawal, every cause confounded, death or last clinical follow-up. Composed PFS and TTF were evaluated only in patients receiving crizotinib followed by a new generation ALKis (in a sequential manner or not), calculated as the sum of the two PFS or TTF, excluding the time lost between the two treatments. OS was defined as the time from the diagnosis of advanced disease to the date of death for any cause or last follow-up. Besides, it was also evaluated from the first ALKis beginning, meaning in this case, OS did not include outcomes of previous regimens in patients receiving other treatments before ALKis. The Kaplan-Meier method was used to calculate PFS, TTF and OS [15, 16] . Statistical analysis was performed using XLStat (2018 version).
Results
Study population description
Clinical features and treatments performed in the study population are summarized in Table 1 and Table S2 . Most of patients (N = 176, 61%) received a chemotherapy agent in first line followed by one or more ALKis mainly consisting in the sequential administration of crizotinib and a new generation ALKis ( Fig. 1 ). Thirty-four percent (N = 98) of the study population performed an ALKis at first and 5% (N = 14) of patients completed crizotinib without receiving any further treatment but no information about withdrawal reasons were collected. Finally, 5% of patients received chemotherapy regimens exclusively in their history of disease. Only one patient was candidate to receive best support care in this cohort.
In the overall population, the median follow-up from diagnosis was 29 months. At time of analysis, 87% (N = 215) of patients experienced a disease progression after crizotinib and 64% (N = 113) after the first new generation ALKi they received. Moreover, 52% (N = 152) of them died. Of note, in the overall population, 29% (N = 85) of patients moved on with the ALKis beyond disease progression but this exceeding time was not taken into account for the PFS analyses.
Outcomes
In the overall population, the crizotinib median PFS was 9.4 months [CI 95% 7.9-11.2] being consistent across the different settings considered (10.7 months in first line [CI 95% 9.0-14.7], 8.1 months in second line [CI 95% 6.7-11.2] and 9.5 months in third or further lines [CI 95% 5.9-11.8], P = 0.278) ( Figure S1 ). Likewise, the median PFS for the first new generation ALK inhibitor received was 11.1 months [CI 95% 9.2-13.8] without differences according to the line of treatment (13.8 Similar results were obtained for the TTF analysis being the crizotinib median TTF of 10.2 months [CI 95% 8.5-12.6] while the median TTF for the first new generation ALKis performed was of 11.9 months [CI 95% 9.7-17.4] without differences appreciable according to the setting considered (P = 0.481 and P = 0.654, respectively) ( Figure S2 ).
The composed outcomes in patients treated with crizotinib followed by a new generation ALKis (sequentially administrated or not) showed a median PFS of 27.8 months [CI 95% 24.3-33.7] and a median TTF of 30.4 months [CI 95% 24.7-34.9]. Once again, these results were consistent regardless of the first ALKis setting line (P = 0.532 and P = 0.725, respectively) ( Figure S1 and S2) .
The median OS from diagnosis of advanced disease was 39 months [CI 95% 31. 8-54.5] . Patients receiving at least an ALKis as part of their treatment strategy (N = 274, 95%) showed a better OS compared to those who performed chemotherapy only [41 months (CI 95% 33.8-55.4) versus 16 months (CI 95% 7.2-NR), P = 0.009]. In particular, patients receiving chemotherapy followed by an ALKis showed a median OS of 39 months [CI 95% 29.8-55.4], while those who performed the ALKis at first had a median OS of 51 months (CI 95% 33.8-65.5) but this difference was not statistically significant in our analysis. Focusing on the type of ALKis performed, patients receiving crizotinib followed by a new generation ALKis with or without chemotherapy agents before showed a higher median OS [57 months (CI 95% 42.0-73.8)] compared to those that did not receive crizotinib [38 months (CI 95% 18.6-NR)], those who performed only crizotinib without any other ALKis within the followed treatments [15 months (CI 95% 11.3-34.0)] (P < 0.0001) (Fig. 2) . These results were consistent even taking into account the different setting in which ALKis were used (first line or later) for each group described above as well as by performing the OS analysis from the first ALKis ( Fig. 2 and Table S3 ). Notably, 30% (44 out of 147) of patients that received crizotinib followed by a new generation ALKis with or without chemotherapy agents before, 34% (10 out of 29) of those that did not received crizotinib and 12% (12 out of 98) of those who performed only crizotinib without any other ALKis, experienced grade III or IV toxicity during ALKis administration. Looking at patient's characteristics, no differences in term of smoking habit, gender or brain metastasis at time of advanced disease diagnosis were found across these groups (Table S4 ).
Discussion
The efficacy of new generation ALKis and their improved central nervous system penetration make them an attractive option for the first line setting. Moreover, a significant proportion of lung cancer patients progressing on first line, for different reasons, could not be able to receive a subsequent line of therapy, making the choice of first ALK inhibitor a crucial decision. In our series, 5% of patients discontinued crizotinib without receiving any further treatment. Unfortunately, no molecular or clinical criteria are currently available to identify the subgroup of patients achieving a higher benefit from crizotinib or those better performing with different approaches. Literature data highlighted the variable predictive role of different ALK fusion variants [17] . Furthermore, specific ALK variants may be associated with ALK resistance mutations, representing a potentially important factor in the upfront ALKi selection, but these approaches are not implemented yet in clinical practice. Moreover, each ALKi is associated with a distinct spectrum of ALK resistance mutations, for some of which, poor treatment options are available [18] . Newer is the ALKi considered, larger is its mutational sensitivity spectrum and harder is to overcome the acquired resistances subsequently raised. The first line choice can then influence the subsequent treatment options and outcomes. Crizotinib has the tightest Despite the head-to-head phase III trials, comparing crizotinib to new generation ALKis in first line, clearly showed a PFS benefit in patients received an upfront new generation agent [3] [4] [5] , we cannot exclude that the sequential use of crizotinib, followed by a new generation agent may improve patient's outcome in some cases. The PROFILE 1014 study showed a positive trend in median OS for patients receiving the sequential strategy (median OS not reached yet) compared to those received chemotherapy and a subsequent ALKi [49.5 months (95% CI 41.0 months to NR)] and those receiving only crizotinib [20.8 months (95% CI 14.4 to 31.8 months)] [19] . However, the recently updated results of the ASCEND 3 trial, described a median OS of 51 months [CI 95% 42.7, 55.3] for patients that received ceritinib as first ALKi in chemotherapy-pretreated patients and headto-head phase III trials results will be soon available [20] . In this proposal, the PFS benefit obtained with crizotinib or a new generation ALKi remained consistent across the lines of treatment considered (first to third line) as already reported by other real-world studies for crizotinib-treated patients [21, 22] and it was coherent with results of clinical trials conducted in the corresponding settings [11-13, 19, 23] . With a median PFS of 34.8 months [CI 95% 17.7-NE] in the ALEX trial, alectinib was the only agent providing a clinical benefit in first line setting markedly different from our findings [6] . However in our study, most of patients performing alectinib, received it in second or later line mainly in crizotinib pretreated patients. The phase III ALUR trial evaluating the alectinib efficacy in this setting showed a median PFS of 7.1 months (95% CI 6.3-10.8) much more consistent with our results.
The composed PFS (27.8 months) and TTF (30.4 months) representing outcomes achieved with crizotinib followed by a new generation ALKis, suggest that crizotinib effect could not be completely adsorbed by the new generation agent and the sequential strategy might confer a clinical benefit in selected patients. Consistently with the final survival analysis of PROFILE 1014, patients receiving nothing but crizotinib as ALKis, showed the worst survival (15 months) once compared to the rest of the study population performing a target agent. Moreover, the sequential administration of crizotinib and a new generation ALKis provided the better outcome in term of survival (57 months), while patients only receiving a new generation ALKis showed an intermediate outcome (39 months). To note, the median OS registered in the group of patients that did not receive any ALKis (16 months) was higher than expected according to the literature data but the sample size (N = 15) was too small to be representative [11, 12, 19] . Anyway this strategy was confirmed to be the less suitable among those considered according to survival results.
These results have to be taken with caution because of the retrospective nature of the study. For instance, we were not allowed to verified information about the performance status of patients or other conditions at baseline possibly affecting the treatment choice. Moreover, the number of patients receiving a new generation ALKis as first target agent is too low (N = 29) to draw conclusions and this is due to the recent introduction into the Italian clinical practice of these drugs in upfront setting. Finally, despite no difference was detected in term of risks factors, including the presence of brain metastasis at baseline, between the different groups considered, we cannot exclude a selection bias in those patients who were able to receive the sequential administration of crizotinib followed by a new generation ALKis potentially having an intrinsically better prognosis. Identifying these patients at baseline is actually the matter. We are currently far from getting ALK variants and mutations analysis into the decision making process and this is mostly due to the rarity of disease not allowing exhaustive results by large randomized trials. However, only biomarker-driven studies, such as the not-comparative phase II NCI-NRG ALK protocol (NCT03737994) assigning different ALKis according to the ALK mutation carried out, will help the comprehension of this intricate field. Finding out the right sequence of ALKis in the right patient will be the next step and the progressive reduction of high throughput technology costs will certainly help us to reach this aim in the future.
Notably, about 60% of patients included in this cohort received a chemotherapy regimen as first-line treatment and 5% of patients did not received any ALKIs during their history of disease. This was certainly due to the late introduction of ALKis in the Italian reimbursed therapeutic arsenal once most of patients included in this analysis were already on-treatment. Nevertheless, a national portrait about molecular profiling in Italian NSCLC patients that we recently published, highlighted that only 60% of those with at least one clinical or histological predictive feature was tested for the ALK rearrangement [24] . Currently, as several ALKis reached the first line setting in many countries, the ALK test has become mandatory at baseline for the treatment decision making.
Despite its several limitations, this study provides an overall survival comparison between different treatment strategies for real-world ALK-rearranged NSCLC patients. Unfortunately, diagnostic samples were not available for most of patients included in this proposal, not allowing a formal comparison with the biological counterpart. For the small proportion of those for which it was recoverable, a separate analysis is ongoing to identify potential predictive factors.
Conclusions
This proposal suggests a longer clinical benefit for the sequential administration of crizotinib followed by a new generation ALKIs strategy compared to other strategies. Despite, this analysis cannot be conclusive considering the small number of patients receiving a new generation ALKis at first and the retrospective nature of the study, the sequential strategy could be an interesting option to consider in selected patients in order to postpone the chemotherapy switching.
